date,title,source
Nov-07-18,"Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in ""Intensive Care Medicine"" and ""The Lancet Respiratory Medicine""",PR Newswire
Nov-13-18,Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview,PR Newswire
Nov-21-18,"Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Nov-26-18,"Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics",American City Business Journals
Dec-04-18,Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations,PR Newswire
Dec-12-18,AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients,PR Newswire
Jan-02-19,Here are the winners and losers from Bay Area's IPO class of 2018,American City Business Journals
